Boston Scientific Corporation (BSX) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Medical Devices
Is Boston Scientific Corporation a safe investment right now?
Boston Scientific Corporation's Altman Z-Score of 4.03 places it in the safe zone. Our fair value estimate is $64.91 (Watch Zone). Moat rating: 2.6/5 stars.
Could Boston Scientific Corporation go bankrupt? Altman Z-Score analysis
Z-Score of 4.03 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives BSX's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.0768 | 1.2 | 0.09 |
| B · Retained Earnings / Total Assets | RE / TA | 0.1276 | 1.4 | 0.18 |
| C · EBIT / Total Assets | EBIT / TA | 0.0855 | 3.3 | 0.28 |
| D · Market Cap / Total Liabilities | MCap / TL | 5.021 | 0.6 | 3.01 |
| E · Revenue / Total Assets | Rev / TA | 0.4596 | 1.0 | 0.46 |
How has BSX's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 4.48 | Safe |
| 2023 | 4.41 | Safe |
| 2024 | 4.08 | Safe |
| 2025 | 4.03 | Safe |
Source: Calculated from BSX's latest 10-K filing on SEC EDGAR.
What is Boston Scientific Corporation actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $2.81 | Proprietary blend of reported actuals (1Q actual) + analyst consensus, weighted by α |
| Last Year EPS | $1.94 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $3.45 | 32 analysts consensus |
| Trailing P/E | 27.1x | Current market pricing |
| Fair P/E (β discount) | 23.1x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Accelerating | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $95.75 (32 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Boston Scientific Corporation have a durable competitive advantage?
Moat rating: 2.6/5.
What makes up BSX's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is BSX's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 6.1% | — |
| 2023 | 7.9% | Rising |
| 2024 | 8.0% | Stable |
| 2025 | 10.5% | Rising |
Source: ROIC calculated from SEC EDGAR filings.
Is Boston Scientific Corporation's dividend safe?
Boston Scientific Corporation's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $20.1B | $16.7B | $12.7B | Rising |
| Net Income | $2.9B | $1.9B | $0.7B | Rising |
| Free Cash Flow | $3.4B | $2.4B | $0.9B | Rising |
| Gross Margin | 69.0% | 68.6% | 68.8% | Stable |
Recent events that affect our BSX analysis
BSX analyst consensus: 97% bullish (32 of 33 analysts)
10 Strong Buy, 22 Buy, 1 Hold, 0 Sell, 0 Strong Sell. Consensus target: $95.75 (47.6% upside). Compare with our independent Fair Value: $64.91.
BSX beat EPS estimates by 1.6%
Reported EPS: $0.80 vs estimate $0.79. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX beat EPS estimates by 2.4%
Reported EPS: $0.80 vs estimate $0.78. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX beat EPS estimates by 5.1%
Reported EPS: $0.75 vs estimate $0.71. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BSX beat EPS estimates by 3.4%
Reported EPS: $0.75 vs estimate $0.73. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BSX beat EPS estimates by 11.5%
Reported EPS: $0.75 vs estimate $0.67. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX beat EPS estimates by 6.6%
Reported EPS: $0.70 vs estimate $0.66. Earnings strength supports our Fair Value of $64.91 (0.1% above current price).
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BSX filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Boston Scientific Corporation
What is Boston Scientific Corporation stock price today?
Boston Scientific Corporation (BSX) stock price is $64.87 as of the latest market close, traded on the NYSE exchange.
What does Boston Scientific Corporation do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
What is Boston Scientific Corporation market cap?
Boston Scientific Corporation has a market capitalization of $96.41B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is BSX in?
Boston Scientific Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. It trades on the NYSE under the ticker symbol BSX.
Is BSX stock overvalued or undervalued?
Based on our valuation model, Boston Scientific Corporation trades 0.1% below our fair value estimate — potentially undervalued.
- FairValueLabs Fair Value: $64.91
- Current Price: $64.87
- Valuation Zone: Watch Zone
What is BSX stock forecast and analyst target price?
Based on 32 Wall Street analysts, the consensus price target for Boston Scientific Corporation is $95.75, implying upside of 47.6% from the current price.
- Analyst High Target: $112.00
- Analyst Low Target: $69.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Boston Scientific Corporation revenue and earnings growing?
Here are the analyst consensus growth estimates for Boston Scientific Corporation:
- Revenue growth (current year est.): 10.7%
- EPS growth (current year est.): 12.9%
- Revenue growth (next year est.): 10.2%
- EPS growth (next year est.): 12.9%
What are Boston Scientific Corporation's key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $20.1B | Rising |
| Net Income | $2.9B | Rising |
| Free Cash Flow | $3.4B | Rising |
| Gross Margin | 69.0% | Stable |
What is BSX's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 27.1x
- Forward P/E (next 12 months est.): 17.0x
- FairValueLabs Fair P/E: 23.1x
How volatile is BSX stock?
Boston Scientific Corporation has a beta of 0.78, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Boston Scientific Corporation have?
Boston Scientific Corporation's balance sheet shows:
- Total Cash: $1.96B
- Total Debt: $11.97B
- Net Cash Position: $-10.01B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
Does Boston Scientific Corporation pay a dividend?
Boston Scientific Corporation does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Boston Scientific Corporation at risk of going bankrupt?
Boston Scientific Corporation's Altman Z-Score is 4.03, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Boston Scientific Corporation have a durable competitive advantage?
Boston Scientific Corporation scores 2.6/5 stars (Narrow moat · eroding) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
How do I buy BSX stock?
BSX shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol BSX
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is BSX a value stock or speculative?
FairValueLabs classifies Boston Scientific Corporation as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Boston Scientific Corporation?
The current CEO of Boston Scientific Corporation is Mr. Michael F. Mahoney.
What is BSX's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $2.39
- Forward EPS (next 12 months est.): $3.82
- Analyst consensus EPS (this year): $3.45
- Analyst consensus EPS (next year): $3.90
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
BSX analysis methodology: How we calculate fair value, Z-Scores, and moat ratings